NDC product
Kanjinti
NDC 55513-132 · Amgen, Inc
Key facts
| Product NDC | 55513-132 |
|---|---|
| Proprietary name | Kanjinti |
| Nonproprietary name | trastuzumab-anns |
| Substances | TRASTUZUMAB |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Amgen, Inc |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA761073 |
| Pharmacologic classes | HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC] |
| Marketing start | Jun 11, 2019 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: